Reaction

Blood Bilirubin Abnormal reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,252 reports · 52 co-occurring drugs

As of the last recalculation, Blood Bilirubin Abnormal appears in 1,252 FAERS reports alongside 52 co-occurring drug terms. The strongest observed disproportionality signal is FULVESTRANT (PRR 23.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Fulvestrant	45	23.5	23.5
Febuxostat Tablets 40 Mg	13	21.5	21.5
Febuxostat Tablets 80 Mg	13	21.5	21.5
Ribociclib	33	17.8	17.8
Anastrozole Tablets	21	16.5	16.5
Sofosbuvir	19	16.2	16.3
Sennosides 8.6 Mg Tablets	19	15.3	15.3
Senna	19	15.2	15.2
Senna Leaf	19	13.9	13.9
Ursosiol	16	13.8	13.9
Avapritinib	10	13.8	13.8
Letrozole Tablets	38	13.5	13.5
Doxorubicin Hydrochloride	26	13.5	13.5
Ursodiol	17	13.1	13.2
Febuxostat	13	13.0	13.0
Eculizumab	41	12.9	12.9
Nilotinib	21	12.0	12.0
Letrozole	43	12.0	12.0
Dapagliflozin	22	11.8	11.8
Sorafenib	14	11.3	11.3
Filgrastim	25	11.3	11.3
Ritonavir 100 Mg	10	11.2	11.2
Fenofibrate	23	11.0	11.0
Anastrozole	23	10.6	10.6
Pazopanib Hydrochloride	17	10.6	10.6
Atazanavir	9	10.5	10.5
Bleomycin Sulfate	6	9.7	9.7
Thiotepa	5	8.7	8.7
Doxorubicin	45	8.7	8.7
Regorafenib	6	8.6	8.6
Busulfan	8	8.5	8.5
Sunitinib Malate	19	8.1	8.1
Mesna Injection	4	8.1	8.1
Erlotinib Hydrochloride	6	8.0	8.0
Mesna	4	7.9	7.9
Velpatasvir And Sofosbuvir	6	7.8	7.8
Glecaprevir And Pibrentasvir	5	7.6	7.6
Vemurafenib	5	6.9	6.9
Erlotinib	4	6.9	6.9
Ribavirin	26	6.8	6.8
Crizotinib	5	6.6	6.6
Lapatinib	6	6.5	6.5
Temozolomide	8	6.3	6.3
Deferasirox	10	6.3	6.3
Eltrombopag Olamine	8	5.8	5.8
Alpelisib	3	5.7	5.7
Cabozantinib	16	5.6	5.6
Fam-Trastuzumab Deruxtecan-Nxki	3	5.0	5.0
Blinatumomab	3	4.8	4.8
Trifluridine And Tipiracil	3	4.7	4.7
Voxelotor	6	4.5	4.5
Tafamidis	3	4.2	4.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.